composition containing surfactant

Abstract

To provide a novel composition (a composition comprising a surfactant).SOLUTION: A composition comprises one nonionic surfactant and one ampholytic surfactant.SELECTED DRAWING: None

Description

Technical Field

[0001] The present invention relates to a novel composition (a composition containing a surfactant) and the like.

Background Art

[0002] A surfactant is a component used as a foaming agent or the like. For example, Patent Document 1 describes a foaming composition for application to skin that contains a specific nonionic surfactant or the like.

Prior Art Literature

Patent Literature

[0003]

Patent Document 1

Summary of Invention

Problem to be Solved by Invention

[0004] An object of the present invention is to provide a novel composition (a composition containing a surfactant) and the like.

Means for Solving the Problem

[0005] As described above, surfactants are used in foaming compositions and the like for application to skin. The present inventors have found that the composition described in Patent Document 1 and the like may not provide sufficient usability in that, for example, stickiness remains when it is foamed and applied to the skin.

[0006] In order to reduce stickiness, the present inventors tried approaches such as reducing the amount of surfactant, but if stickiness was reduced, sufficient foaming properties could not be obtained, and it was difficult to achieve both reduction in stickiness and foaming properties.

[0007] Under these circumstances, the inventors discovered that by combining one type of nonionic surfactant with one type of amphoteric surfactant, it is possible to achieve both reduced stickiness and foaming properties. Through further diligent research, they completed the present invention.

[0008] In other words, the present invention relates to the following inventions, etc. [1] A composition containing one nonionic surfactant and one amphoteric surfactant. [2] A composition containing a nonionic surfactant and one amphoteric surfactant, wherein the total amount of nonionic surfactant in the composition is 2.3% by mass or less. [3] A composition for aerosol foam formulations containing a nonionic surfactant and one amphoteric surfactant, but not containing a nonionic surfactant with an HLB value of 14 or higher. [4] A composition for aerosol foam formulations, containing a nonionic surfactant and one amphoteric surfactant, wherein the nonionic surfactant is present in a ratio of 20 parts by mass or less per 1 part by mass of the amphoteric surfactant. [5] The composition according to any one of [1] and [3] to [4], wherein the proportion of nonionic surfactant in the composition is 2.3% by mass or less. [6] The composition according to any one of [1] to [5], wherein the amphoteric surfactant is a phospholipid. [7] The composition according to [6], wherein the phospholipid is lecithin. [8] The composition according to [7], wherein the lecithin is hydrogenated lecithin with a phosphatidylcholine content of less than 50% by mass. [9] A composition according to any one of [1] to [2] and [4] to [8], comprising a nonionic surfactant having an HLB of 10 to 20.

[10] A composition according to any one of [1] to [9], wherein the nonionic surfactant comprises a polyoxyethylene fatty acid ester.

[11] The composition according to any one of [1] to

[10] , wherein the nonionic surfactant comprises polyoxyethylene monofatty acid ester.

[12] The composition according to any one of [1] to

[11] , wherein the proportion of the nonionic surfactant is 2 parts by mass or more and 50 parts by mass or less relative to 1 part by mass of the amphoteric surfactant.

[13] The composition according to any one of [1] to

[12] , further comprising glycerin.

[14] The composition according to any one of [1] to

[13] , further comprising an active ingredient.

[15] The composition according to

[14] , wherein the active ingredient comprises a heparin-like substance.

[16] The composition according to any one of [1] to

[15] , wherein the components constituting the composition are in a dissolved state or are not separated.

[17] The composition according to any one of [1] to

[16] , which is for leave-on use.

[18] The composition according to any one of [1] to

[17] , which is foamable.

[19] The composition according to any one of [1] to [2] and [5] to

[18] , which is for a pump-type foam formulation or an aerosol-type foam formulation.

[20] The composition according to any one of [1] to [2] and [5] to

[19] , which is for a pump-type foam formulation, and the components constituting the composition are in a dissolved state or are not separated.

[21] The composition according to any one of [1] to

[20] , which is an external composition for skin.

[22] The composition according to any one of [1] to [2] and [5] to

[21] , which is for a pump-type foam formulation, and the nonionic surfactant comprises a nonionic surfactant having an HLB of 13 to 18.

[23] The composition according to any one of [1] to

[21] , which is for an aerosol foam formulation, and the nonionic surfactant comprises a nonionic surfactant having an HLB of 11 to 13.

[24] The composition according to any one of [1] to

[23] , which does not contain a polymer thickener.

[25] The composition according to any one of [1] to

[24] , which further comprises a propellant, and the propellant is LPG.

[26] The composition according to any one of [1] to

[25] , which does not (substantially) contain an anionic surfactant. Advantageous Effects of Invention

[0009] According to the present invention, a novel composition (a composition containing a surfactant) can be provided.

[0010] According to one aspect of the composition of the present invention, stickiness when foamed and applied to the skin can be reduced.

[0011] According to one aspect of the composition of the present invention, the composition can foam efficiently. In particular, when discharged by a pump or sprayed with a gas, good foamability can be achieved (that is, good foam can be formed).

[0012] According to one aspect of the composition of the present invention, good foamability can be achieved even when the proportion of the nonionic surfactant in the composition is relatively low.

[0013] According to one aspect of the composition of the present invention, both reduced stickiness and good foamability can be achieved when the composition is foamed and applied to the skin.

[0014] One aspect of the composition of the present invention can be in a dissolved state or an unseparated state. Such a composition can be suitably used as a composition for pump foam formulations.

[0015] One aspect of the composition of the present invention is excellent in compatibility with a propellant. Such compositions can be suitably used for aerosol foam formulations. [Modes for carrying out the invention]

[0016] [Composition] The composition (formulation) of the present invention contains a nonionic surfactant and an amphoteric surfactant. The composition can be used, for example, for pump-type foam formulations, aerosol-type foam formulations, and the like.

[0017] (Composition of the first aspect) The composition of the first embodiment contains one nonionic surfactant and one amphoteric surfactant.

[0018] Nonionic surfactants Examples of nonionic surfactants include polyoxyethylene fatty acid esters, polyglycerin fatty acid esters, PEG [polyethylene glycol or polyoxyethylene (POE)] hydrogenated castor oil (POE hydrogenated castor oil), POE castor oil, sorbitan fatty acid esters, POE sorbitan fatty acid esters, polyoxyethylene polyoxypropylene (POP) glycol, POE alkyl ethers, POE-POP alkyl ethers, POE alkylphenyl ethers, and the like.

[0019] In polyoxyethylene fatty acid esters, the fatty acid may be a saturated fatty acid or an unsaturated fatty acid. Examples of fatty acids include C 8―24 Alkyl or alkenyl (preferably C 10―20 Examples include alkyl or alkenyl carboxylic acids. The polyoxyethylene fatty acid ester may be a monoester (polyoxyethylene mono fatty acid ester) or a diester (polyoxyethylene di fatty acid ester). In the polyoxyethylene fatty acid ester, the average number of moles of polyoxyethylene added may be, for example, 2 to 150. Typical polyoxyethylene fatty acid esters include, for example, polyethylene glycol laurate (e.g., mono- or dilaurate polyethylene glycol), polyethylene glycol stearate (e.g., mono- or distearate polyethylene glycol), and polyethylene glycol oleate (e.g., mono- or dioleate polyethylene glycol).

[0020] In polyglycerol fatty acid esters, examples of fatty acids include those exemplified above. Polyglycerol fatty acid esters may be monoesters (polyglycerol mono fatty acid esters), diesters (polyglycerol di fatty acid esters), triesters (polyglycerol tri fatty acid esters), etc. Representative polyglycerol fatty acid esters include, for example, polyglyceryl oleate (e.g., mono- or tri-oleate polyglyceryl), polyglyceryl laurate (e.g., mono- or tri-laurate polyglyceryl), polyglyceryl myristate (e.g., mono- or tri-myristate polyglyceryl), and polyglyceryl stearate (e.g., mono- or tri-tristearate polyglyceryl).

[0021] In sorbitan fatty acid esters, examples of fatty acids include those exemplified above. Sorbitan fatty acid esters may be monoesters (sorbitan mono fatty acid esters), diesters (sorbitan di fatty acid esters), triesters (sorbitan tri fatty acid esters), etc. Representative sorbitan fatty acid esters include, for example, sorbitan laurate (e.g., mono- or trilaurate sorbitan), sorbitan palmitate (e.g., mono- or tripalmitate sorbitan), sorbitan stearate (e.g., mono- or tristearate sorbitan), and sorbitan oleate (e.g., mono- or trioleate sorbitan).

[0022] The POE sorbitan fatty acid ester (polysorbate) may be the sorbitan fatty acid ester exemplified above to which polyoxyethylene has been added. In the POE sorbitan fatty acid ester, the average number of moles of polyoxyethylene added may be, for example, 20 to 85. Representative POE sorbitan fatty acid esters include polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, and polysorbate 85.

[0023] Examples of POEPOP glycols include poloxamer 407, poloxamer 403, poloxamer 235, and poloxamer 188.

[0024] Examples of POE alkyl ethers include POEC 8―24 Examples include alkyl ethers (e.g., POE lauryl ether).

[0025] Examples of POE-POP alkyl ethers include POEPOPC 8―24 Examples include alkyl ethers (e.g., POEPOP cetyl ether).

[0026] Examples of POE alkylphenyl ethers include POEC 8―24 Examples include alkylphenyl ethers (e.g., POE nonylphenyl ether).

[0027] In the compounds exemplified above, POE represents polyoxyethylene and POP represents polyoxypropylene.

[0028] Among the above nonionic surfactants, polyoxyethylene fatty acid esters (e.g., polyethylene glycol laurate, polyethylene glycol stearate, polyethylene glycol oleate, etc.) are preferred, and polyoxyethylene mono fatty acid esters (e.g., polyethylene glycol monolaurate, polyethylene glycol monostearate, polyethylene glycol monooleate, etc.) are preferred.

[0029] The HLB value of the nonionic surfactant may be, for example, 5 to 30, preferably 10 to 20. For example, if the composition is for a pump-type foam formulation, the HLB value of the nonionic surfactant may be, for example, 10 to 20, preferably 13 to 18 (for example, 14 to 17), from the viewpoint of dispersibility in aqueous solution. When the composition is for an aerosol foam formulation, the HLB value of the nonionic surfactant may be, for example, 5 to 15, preferably 8 to 13 (for example, 11 to 13), from the viewpoint of propellant dispersibility and the like.

[0030] In the composition of the first embodiment, the proportion of the nonionic surfactant may be, for example, 20% by mass or less (e.g., 15% by mass or less), preferably 10% by mass or less (e.g., 5% by mass or less), more preferably 3% by mass or less (e.g., 2.5% by mass or less, 2.3% by mass or less, 2% by mass or less) relative to the whole composition, and may also be, for example, 0.001% by mass or more, 0.01% by mass or more, 0.1% by mass or more, etc.

[0031] Amphoteric surfactants Examples of amphoteric surfactants include betaine-type amphoteric surfactants such as carboxybetaine type (e.g., alkyldimethylaminoacetic acid betaine, fatty acid amidopropyl betaine, etc.), sulfobetaine type (e.g., alkyl sulfobetaine, alkyl hydroxysulfobetaine, etc.), and imidazoline-based betaine type (e.g., alkylcarboxymethylhydroxyethylimidazolinium betaine, etc.); and phospholipids. Among these, phospholipids and the like are preferred from the viewpoint of foaming ability and reduction of stickiness during application.

[0032] Examples of phospholipids include lecithins, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingophospholipids, sphingolipids (e.g., sphingomyelin), phosphatidic acid, lysophosphatidylcholine, etc., with lecithins being preferred.

[0033] Lecithins may be natural or synthetic. Natural lecithins may be extracted from plants or animals (e.g., soybeans, egg yolks, corn, etc.). Among lecithins, hydrogenated lecithin is preferred. In hydrogenated lecithin, the phosphatidylcholine content is not particularly limited and may be, for example, 50% by mass or more (e.g., 60% by mass or more, 70% by mass or more, 80% by mass or more, 90% by mass or more). Alternatively, in hydrogenated lecithin, the phosphatidylcholine content may be, for example, 70% by mass or less (e.g., 65% by mass or less), preferably 60% by mass or less (e.g., 55% by mass or less), more preferably 50% by mass or less (e.g., less than 50% by mass), and may also be, for example, 20% by mass or more (e.g., 25% by mass or more, 30% by mass or more, 35% by mass or more, 40% by mass or more). In this invention, even hydrogenated lecithin with a relatively low phosphatidylcholine content, such as less than 50% by mass, can exhibit foaming properties and reduced stickiness. Furthermore, hydrogenated lecithin with such a relatively low phosphatidylcholine content usually does not require purification.

[0034] In the composition of the first embodiment, the proportion of the amphoteric surfactant may be, for example, 0.01% by mass or more (e.g., 0.02% by mass or more), preferably 0.03% by mass or more (e.g., 0.04% by mass or more), more preferably 0.05% by mass or more (e.g., 0.07% by mass or more), relative to the whole composition, or for example, 1% by mass or less, preferably 0.7% by mass or less, more preferably 0.5% by mass or less (e.g., 0.3% by mass or less, 0.2% by mass or less), etc.

[0035] In the composition of the first embodiment, the proportion of the nonionic surfactant (ratio to the amphoteric surfactant) may be, for example, 1.5 parts by mass or more (for example, 2 parts by mass or more), preferably 5 parts by mass or more (for example, 8 parts by mass or more), more preferably 10 parts by mass or more (for example, 15 parts by mass or more), per 1 part by mass of the amphoteric surfactant, and may also be, for example, 60 parts by mass or less, 50 parts by mass or less, 40 parts by mass or less, 30 parts by mass or less, 20 parts by mass or less, etc. For example, if the composition is for a pump-type foam formulation, the proportion of the nonionic surfactant in the composition may be, for example, 5 parts by mass or more (e.g., 10 parts by mass or more), preferably 15 parts by mass or more (e.g., 20 parts by mass or more), more preferably 25 parts by mass or more (e.g., 30 parts by mass or more), per 1 part by mass of the amphoteric surfactant, or for example, 60 parts by mass or less, 50 parts by mass or less, 40 parts by mass or less, etc. When the composition is for an aerosol foam formulation, the proportion of the nonionic surfactant in the composition may be, for example, 1.5 parts by mass or more (e.g., 2 parts by mass or more), preferably 3 parts by mass or more (e.g., 5 parts by mass or more), more preferably 7 parts by mass or more (e.g., 10 parts by mass or more), per 1 part by mass of the amphoteric surfactant, or for example, 30 parts by mass or less, 20 parts by mass or less, 10 parts by mass or less, etc.

[0036] In the composition of the first embodiment, the total amount ratio of nonionic surfactants and amphoteric surfactants may be, for example, 30% by mass or less (e.g., 25% by mass or less), preferably 20% by mass or less (e.g., 15% by mass or less), more preferably 10% by mass or less (e.g., 5% by mass or less, 4% by mass or less, 3% by mass or less, 2.5% by mass or less) relative to the whole composition, and may also be, for example, 0.01% by mass or more, 0.1% by mass or more, 1% by mass or more, etc.

[0037] (Composition of the second aspect) The composition of the second embodiment contains a nonionic surfactant and one amphoteric surfactant. In the composition of the second embodiment, the total amount of nonionic surfactant in the composition may be, for example, 2.3% by mass or less.

[0038] In the composition of the second embodiment, one or more of the nonionic surfactants exemplified in the composition of the first embodiment may be used, and it is preferable that the composition contains a polyoxyethylene fatty acid ester. Preferred polyoxyethylene fatty acid esters may be those exemplified in the composition of the first embodiment, etc.

[0039] In the composition of the second embodiment, the amphoteric surfactant may be one of those exemplified in the composition of the first embodiment. Preferred amphoteric surfactants may be those exemplified in the composition of the first embodiment, etc.

[0040] In the composition of the second embodiment, the proportion of the nonionic surfactant (total amount) may be, for example, 2.3% by mass or less (for example, 2.2% by mass or less, 2.1% by mass or less, 2% by mass or less, etc.) relative to the whole composition, or for example, 0.001% by mass or more, 0.01% by mass or more, 0.1% by mass or more, etc.

[0041] In the composition of the second embodiment, the proportion of the amphoteric surfactant may be the same as in the composition of the first embodiment.

[0042] In the composition of the first embodiment, the ratio of the nonionic surfactant (total amount) to the amphoteric surfactant may be the same as that of the composition of the first embodiment described above.

[0043] In the composition of the second embodiment, the ratio of the total amount of nonionic surfactant to amphoteric surfactant may be the same as that of the composition of the first embodiment.

[0044] (Composition of the third aspect) The composition of the third embodiment contains a nonionic surfactant and one amphoteric surfactant. The composition of the third embodiment typically does not contain a nonionic surfactant with an HLB value of 14 or higher. Such a composition may be used for aerosol foam formulations.

[0045] In the composition of the third embodiment, one or more of the nonionic surfactants exemplified in the composition of the first embodiment may be used, and it is preferable that the composition contains a polyoxyethylene fatty acid ester. Preferred polyoxyethylene fatty acid esters may be those exemplified in the composition of the first embodiment, etc. In the composition of the third embodiment, the HLB value of the nonionic surfactant does not need to be 14 or higher, and may be, for example, 8 to 13, preferably 11 to 13.

[0046] In the composition of the third embodiment, the amphoteric surfactant may be one of those exemplified in the composition of the first embodiment. Preferred amphoteric surfactants may be those exemplified in the composition of the first embodiment, etc.

[0047] In the composition of the third embodiment, the proportion of the nonionic surfactant (total amount) may be the same as in the composition of the first embodiment described above.

[0048] If the composition of the third embodiment contains a polyoxyethylene fatty acid ester, the proportion of the polyoxyethylene fatty acid ester in the composition of the third embodiment may be, for example, 10% by mass or less (for example, 8% by mass or less), preferably 5% by mass or less (for example, 3% by mass or less), more preferably 2.5% by mass or less (for example, 2.3% by mass or less, 2.2% by mass or less, 2.1% by mass or less, 2% by mass or less, etc.) relative to the whole composition, and may also be, for example, 0.001% by mass or more, 0.01% by mass or more, 0.1% by mass or more, etc.

[0049] In the composition of the third embodiment, the proportion of the amphoteric surfactant may be the same as in the composition of the first embodiment.

[0050] In the composition of the third embodiment, the proportion of the nonionic surfactant (total amount) may be, for example, 1.5 parts by mass or more (for example, 2 parts by mass or more), preferably 3 parts by mass or more (for example, 5 parts by mass or more), more preferably 7 parts by mass or more (for example, 10 parts by mass or more), per 1 part by mass of the amphoteric surfactant, and may also be, for example, 30 parts by mass or less, 20 parts by mass or less, 10 parts by mass or less, etc.

[0051] In the composition of the third embodiment, the ratio of the total amount of nonionic surfactant to amphoteric surfactant may be the same as that of the composition of the first embodiment.

[0052] (Composition of the fourth aspect) The composition of the fourth embodiment contains a nonionic surfactant and one amphoteric surfactant. The composition of the fourth embodiment typically contains 20 parts by mass or less of the nonionic surfactant per 1 part by mass of the amphoteric surfactant. Such a composition may be used for aerosol foam formulations.

[0053] In the composition of the fourth embodiment, one or more of the nonionic surfactants exemplified in the composition of the first embodiment may be used, and it is preferable that the composition contains a polyoxyethylene fatty acid ester. Preferred polyoxyethylene fatty acid esters may be those exemplified in the composition of the first embodiment, etc.

[0054] In the composition of the fourth embodiment, the amphoteric surfactant may be one of those exemplified in the composition of the first embodiment. Preferred amphoteric surfactants may be those exemplified in the composition of the first embodiment, etc.

[0055] In the composition of the fourth embodiment, the proportion of the nonionic surfactant (total amount) may be the same as the proportion exemplified in the composition of the first embodiment.

[0056] If the composition of the fourth embodiment contains a polyoxyethylene fatty acid ester, the proportion of the polyoxyethylene fatty acid ester in the composition of the fourth embodiment may be the same as the proportion exemplified in the composition of the third embodiment.

[0057] In the composition of the fourth embodiment, the proportion of the amphoteric surfactant may be the same as in the composition of the first embodiment described above.

[0058] In the composition of the fourth embodiment, the ratio of nonionic surfactant (total amount) to 1 part by mass of amphoteric surfactant may be, for example, 20 parts by mass or less, preferably 15 parts by mass or less, more preferably 10 parts by mass or less, and may be, for example, 1.5 parts by mass or more, 2 parts by mass or more, 5 parts by mass or more, etc.

[0059] In the composition of the fourth embodiment, the total ratio of nonionic surfactants to amphoteric surfactants may be the same as that of the composition of the first embodiment.

[0060] Other ingredients The compositions of the present invention (compositions of the first, second, third, and fourth embodiments) may contain other components.

[0061] Other components can be selected depending on the intended use and form of the composition, and examples include active ingredients, viscosity modifiers (thickeners such as viscosity modifiers and polymer thickeners), foaming agents, bactericidal (antibacterial) agents, preservatives, cationic surfactants, anionic surfactants, deodorants, fragrances, stabilizers, modifiers, plasticizers, solubilizers, reducing agents, buffers, bases, volatilization aids, flavoring agents, synergists, suspending agents, antioxidants, efficacy enhancers, sustaining agents, wetting modifiers, fillers, defoaming agents, cooling agents, enhancers, fragrances, colorants, isotonic agents, softeners, emulsifiers, foaming agents, skin protectants, flotation agents, dispersants, propellants, fragrances, rust inhibitors, preservatives, solvents, and solubilizers.

[0062] Furthermore, other ingredients may possess multiple functions.

[0063] Examples of other such ingredients include, for example, active ingredients (e.g., heparinoids, panthenol, diphenhydramine, crotamiton, nicotinamide, tranexamic acid, placenta extract, and other vitamins), polyhydric alcohols {e.g., alkanediols (e.g., ethylene glycol, propylene glycol, 1,3-butylene glycol, 1,4-butanediol, 3-methyl-1,3-Butanediol, pentanediol), polymers of alkanediols (e.g., diethylene glycol, triethylene glycol, dipropylene glycol), polyethylene glycol (macrogol), polyoxyethylene polyoxypropylene glycol (poloxamer), polyhydric alcohols having 3 or more hydroxyl groups [e.g., glycerin, diglycerin, sugars or sugar alcohols (e.g., trehalose, etc.)], polysaccharides or their derivatives (e.g., hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydrophobized hydroxypropylmethylcellulose, carboxymethylcellulose (sodium carboxymethylcellulose), guar gum, carrageenan, locust bean gum, xanthan gum, etc.), cationic surfactants (e.g., cetylpyridinium chloride, benzethonium chloride, decalinium chloride, didecyldimethylammonium chloride, N-coconut oil fatty acid acyl-L-arginine ethyl DL-pyrrolidone carboxylate, etc.), antibacterial agents or preservatives [e.g., phenoxyethanol, chlorhexidine gluconate] [, benzoic acid or its salt (sodium benzoate, etc.), dehydroacetic acid or its salt (sodium dehydroacetate, etc.), glycyrrhizic acid or its salt (dipotassium glycyrrhizate, etc.), etc.], solubilizers (e.g., isopropyl myristate, etc.), solubilizers (e.g., glycerin fatty acid esters, etc.), stabilizers (e.g., tocopherol acetate, etc.), pH adjusters [e.g., inorganic acids (hydrochloric acid, sulfuric acid, etc.), organic acids (lactic acid, sodium lactate, citric acid, sodium citrate, succinic acid, sodium succinate and their hydrates, etc.), inorganic bases (hydroxyl Examples include potassium, sodium hydroxide, etc., organic bases (triethanolamine, diisopropanolamine, triisopropanolamine, etc.), stabilizers (e.g., methyl benzoate, propyl benzoate, and other benzoic acid esters), humectants or softeners (e.g., allantoin, urea, 2-methacryloyloxyethyl phosphorylcholine / butyl methacrylate copolymer solution (Lipidure®), ceramide, amino acids, hyaluronic acid and / or its salts, chondroitin sulfate and / or its salts, squalane, white petrolatum, etc.).

[0064] Other ingredients may be used individually or in combination of two or more.

[0065] If the composition contains other components, the proportion of these other components can be appropriately selected according to their type, intended use, and other factors.

[0066] The proportion of other components (total amount) in the composition may be, for example, 60% by mass or less, preferably 50% by mass or less, more preferably 40% by mass or less (for example, 30% by mass or less, 20% by mass or less, 15% by mass or less, 10% by mass or less, etc.) relative to the whole composition, or it may be 0.001% by mass or more, preferably 0.01% by mass or more, more preferably 0.1% by mass or more (for example, 0.15% by mass or more, 0.2% by mass or more, etc.).

[0067] If the composition contains a heparin-like substance, the proportion of the heparin-like substance in the composition may be, for example, 20% by mass or less (e.g., 15% by mass or less), preferably 10% by mass or less (e.g., 5% by mass or less), more preferably 3% by mass or less (e.g., 2% by mass or less, 1% by mass or less, 0.5% by mass or less), relative to the entire composition, and may also be, for example, 0.001% by mass or more, 0.01% by mass or more, 0.1% by mass or more, etc.

[0068] Furthermore, if the composition contains an anionic surfactant as another component, from the viewpoint of reducing skin irritation when used as a skin composition, the proportion of anionic surfactant in the composition is preferably relatively small [for example, 1% by mass or less (for example, 0.5% by mass or less, 0.1% by mass or less, 0.01% by mass or less, etc.)], and it is more preferable that it is substantially not present.

[0069] solvent The compositions of the present invention (compositions of the first, second, third, and fourth embodiments) may contain a solvent (base or carrier, solvent component).

[0070] Examples of solvents include water, non-aqueous solvents [for example, lower alcohols (e.g., ethanol, isopropanol, etc.), polyhydric alcohols (e.g., glycerin, 1,3-butylene glycol, propylene glycol, polyethylene glycol (macrogol), isoprene glycol, dipropylene glycol, and other polyhydric alcohols mentioned above)].

[0071] The solvent may be used alone or in combination of two or more types.

[0072] Furthermore, other components such as the pH adjuster mentioned above can also be used as non-aqueous solvents.

[0073] Non-aqueous solvents may typically be water-soluble solvents (or solvents that are miscible with water).

[0074] The solvent is preferably composed of at least water. That is, the composition of the present invention may usually contain at least water, and may also contain water and a non-aqueous solvent.

[0075] The proportion of solvent (total amount) in the composition may be, for example, 30% by mass or more, 40% by mass or more, 50% by mass or more, 60% by mass or more, 70% by mass or more, etc., or 90% by mass or less, 85% by mass or less, 80% by mass or less, etc.

[0076] If the composition contains polyhydric alcohols, the proportion of polyhydric alcohols (total amount) in the composition may be, for example, 5% by mass or more, 8% by mass or more, 10% by mass or more, 15% by mass or more, 20% by mass or more, etc., or 70% by mass or less, 60% by mass or less, 50% by mass or less, 40% by mass or less, etc.

[0077] [Form / manufacturing method] The form (properties) of the compositions of the present invention (compositions of the first, second, third, and fourth embodiments) is not particularly limited, but may be liquid. The liquid compositions may be solutions, suspensions, emulsions, etc., depending on the components of the composition. Liquid compositions may have components that are dissolved or not separated. In particular, when the composition is for a pump-type foam formulation, it is preferable that the components that make up the composition are dissolved or not separated.

[0078] The composition (the composition at the time of use) may be in the form of a mist, foam, etc. That is, the composition may be foaming and may become a mist or foam when discharged or sprayed from a container.

[0079] The composition can be obtained by mixing the components. The mixing may involve mixing all components at once, or by mixing two or more pre-prepared components first, and then mixing the remaining components. The mixing method (manufacturing method) is not particularly limited, and conventional methods can be used.

[0080] [Application] The uses of the compositions of the present invention (compositions of the first, second, third, and fourth embodiments) are not particularly limited. The compositions can be used, for example, as topical compositions (topical preparations), and especially as skin compositions (topical skin compositions).

[0081] Such compositions (external compositions) may be cosmetics, pharmaceuticals (external pharmaceuticals), or quasi-drugs.

[0082] Such compositions are suitable for use in leave-on applications, where they are not rinsed off.

[0083] [How to use] The composition of the present invention (compositions of the first, second, third, and fourth embodiments) can be used in any way appropriate depending on the purpose of use of the composition, and can be used, for example, by applying it to the target (application) area.

[0084] One specific application method is application (adhesion) to the target area. For example, the composition may be dispensed or sprayed from a container and applied as a foam or mist. The composition may be contained in a suitable container. The container can be selected according to the application method.

[0085] For example, the composition may be applied in a foamy form by placing it in a foam-forming container (e.g., a foam bottle) and dispensing it from the container. The composition may also be applied in a mist form by placing it in a spray container (spray bottle) together with a propellant (for example, compressed gas such as LPG) and spraying it from the container.

[0086] The amount of the composition to be applied (used) will vary depending on the condition of the skin, age, gender, etc., but it may be used in the following way, for example. For example, a composition containing an active ingredient (e.g., a heparin-like substance) may be applied to the skin several times a day (e.g., about 1 to 5 times) in an appropriate amount (e.g., about 0.05 to 5 g), and the composition may be applied so that the daily amount of the active ingredient (e.g., a heparin-like substance) used is, for example, about 0.01 to 100 mg. The application period is not particularly limited.

[0087] The composition may be applied to healthy individuals or to individuals with various diseases (or symptoms). [Examples]

[0088] The present invention will be described in more detail below with reference to examples, but the present invention is not limited thereto.

[0089] Example 1 (Pump-type foam formulation) A 2-methacryloyloxyethyl phosphorylcholine / butyl methacrylate copolymer solution was added to the aqueous solvent listed in Table 1 and mixed. To the resulting solution, all the remaining components listed in Table 1 were added and mixed at room temperature. The mixture was then stirred while raising the temperature to 80°C, then stirred while cooling to 30°C, and finally returned to room temperature to obtain the composition. The components of the obtained composition were in a dissolved state. In Table 1, % indicates mass %. Lipidure-PMB (manufactured by NOF Corporation) was used as the 2-methacryloyloxyethyl phosphorylcholine / butyl methacrylate copolymer solution, NIKKOL MYS-25V (manufactured by Nikko Chemicals Co., Ltd.) was used as the polyethylene glycol monostearate, and NIKKOL Resinol S-10 (manufactured by Nikko Chemicals Co., Ltd.) was used as the hydrogenated soybean phospholipid.

[0090] [Table 1]

[0091] Evaluation Test The composition obtained above was placed in a foaming bottle. Approximately 1g of the foaming bottle was applied to the forearms (from the elbow to the wrist) of five human subjects, and a sensory evaluation was conducted. The evaluation method is shown below. For the evaluations 1-4 below, the average value of 5 people was calculated. Rating 1: Foam elasticity (1: weak ⇔ 5: strong) Rating 2: Foam persistence (1: short ⇔ 5: long) Rating 3: Stickiness immediately after application (1: weak ⇔ 5: strong) Rating 4: Moisturizing effect 5 minutes after application (1: weak ⇔ 5: strong) Rating 5: If you would like to continue using this foam formulation, including its feel and moisturizing properties, then ○; otherwise, ×.

[0092] Foam strength and moisturizing properties Based on evaluations 1-4 above, foam strength and moisturizing properties were evaluated using the following evaluation method. Foam strength = (Average value of evaluation 1 + Average value of evaluation 2) / 2 Moisture retention = (Average value of rating 3 + Average value of rating 4) / 2

[0093] Foaming, foam disappearance, white cast foaming The foaming action when dispensing from a foaming bottle (pump-type foamer) was visually inspected and evaluated. ◎: Very good ○: Good △: Has some foaming properties ×: Did not produce foam. Foam disappears The disappearance of foam dispensed from a foaming bottle (pump-type foamer) was visually observed and evaluated. ○: The foam lasted well. △: The bubbles did not disappear immediately. ×: The bubbles disappeared immediately. Whitening The white residue left on the skin after applying foam dispensed from a foaming bottle (pump-type foamer) was visually inspected and evaluated. ○: After applying it once and spreading it out, the remaining foam (white residue) immediately disappeared. △: After applying it several times, the remaining foam (white cast) disappeared. ×: No matter how many times I spread it, the white residue did not disappear.

[0094] Reference example 1 A composition was obtained in the same manner as in Example 1, except that hydrogenated soybean phospholipids were not used. The obtained compositions were evaluated in the same manner as in Example 1.

[0095] Comparative Example 1 Instead of the composition used in Example 1, a commercially available product (Nitto Medic Awawa Heparinoid Foam) was used, and the same evaluation as in Example 1 was performed.

[0096] The evaluation results for Example 1, Reference Example 1, and Comparative Example 1 are shown in Table 2 below.

[0097] [Table 2]

[0098] As shown in Table 2, in Example 1, foaming properties were obtained while suppressing stickiness immediately after application. In addition, in Example 1, moisturizing properties were obtained while suppressing stickiness immediately after application.

[0099] Example 2 (Aerosol foam formulation) All components other than the aqueous solvent listed in Table 3 were added to the pre-mixed aqueous solvent listed in Table 3 and mixed at room temperature. Then, the mixture was stirred while raising the temperature to 80°C, stirred while cooling to 30°C, and then returned to room temperature. To the resulting stock solution, the propellant (LPG) was added so that the stock solution:propellant (mass ratio) was 92:8, and then the mixture was filled into an aerosol can. In Table 3, percentages represent mass percentages. NIKKOL MYL-10 (manufactured by Nikko Chemicals Co., Ltd.) was used as the polyethylene glycol monolaurate, and NIKKOL Resinol S-10 (manufactured by Nikko Chemicals Co., Ltd.) was used as the hydrogenated soybean phospholipid.

[0100] [Table 3]

[0101] Comparative Example 2 In Example 2, a commercially available product (Maruho Hirudoid Foam) was used for evaluation instead of the aerosol can prepared in Example 2.

[0102] The aerosol cans used in Example 2 and Comparative Example 2 were used, and the evaluation was carried out in the same manner as above, except that the number of subjects was 7. The results are shown in Table 4 below.

[0103] [Table 4]

[0104] As shown in Table 4, in Example 2, foaming properties were obtained while suppressing stickiness immediately after application. In addition, in Example 2, moisturizing properties were obtained while suppressing stickiness immediately after application. [Industrial applicability]

[0105] According to the present invention, it is possible to provide compositions and the like that are useful for pump-type foam formulations, aerosol-type foam formulations, and the like.

Claims

1. A composition for aerosol foam formulations containing a nonionic surfactant and one amphoteric surfactant, wherein the nonionic surfactant is present in a ratio of 2 parts by mass to 20 parts by mass per 1 part by mass of the amphoteric surfactant. Furthermore, it contains a heparin-like substance, There is only one type of nonionic surfactant, The nonionic surfactant contains polyoxyethylene monofatty acid ester, The amphoteric surfactant is lecithin. The proportion of nonionic surfactant in the composition is 2.3% by mass or less. A composition in which the proportion of an amphoteric surfactant is 0.03% by mass or more.

2. The composition according to claim 1, wherein the proportion of nonionic surfactant in the composition is 1% by mass or less.

3. The composition according to claim 1 or 2, wherein the lecithin is hydrogenated lecithin with a phosphatidylcholine content of less than 50% by mass.

4. The composition according to any one of claims 1 to 3, wherein the nonionic surfactant has an HLB of 10 to 20.

5. Nonionic surfactants include polyoxyethylene monoC ８―２４ The composition according to any one of claims 1 to 4, wherein the composition is an alkyl or alkenyl carboxylic acid ester.

6. Nonionic surfactants include polyoxyethylene monoC １０―２０ The composition according to any one of claims 1 to 5, wherein the composition is an alkyl or alkenyl carboxylic acid ester.

7. Furthermore, the composition according to any one of claims 1 to 6, further containing glycerin.

8. The composition according to any one of claims 1 to 7, wherein the nonionic surfactant is polyoxyethylene monostearate ester.

9. The composition according to any one of claims 1 to 7, wherein the nonionic surfactant is polyoxyethylene monolaurate ester.

Images